• 1
    Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001; 345: 1098104.
  • 2
    Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, on behalf of the BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48: 21227.
  • 3
    Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004; 50: 3729.
  • 4
    Mohan AK, Cote TR, Block JA, Manadan AM, Siegel JN, Braun MM. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 2004; 39: 2959.
  • 5
    Gardam MA, Kyestone EC, Menzies R, Manners S, Skamene E, Long R, et al. Anti-tumor necrosis factor agents and tuberculosis risk: mechanism of action and clinical management. Lancet Infect Dis 2003; 3: 14855.
  • 6
    Furst DE, Cush J, Kaufmann S, Siegel J, Kurth R. Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents. Ann Rheum Dis 2002; 61: 623.
  • 7
    Mariette X, Salmon D, and the Group RATIO. French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann Rheum Dis 2003; 62: 791.
  • 8
    BIOBADASER group. BIOBADASER: six-monthly update report. Rev Esp Reumatol 2004; 31: 47991.
  • 9
    Carmona L, Hernandez-Garcia C, Vadillo C, Pato E, Balsa A, Gonzalez-Alvaro I, Belmonte MA, et al, and the EMECAR Study Group. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 2003; 30: 14369.
  • 10
    Gonzalez-Alvaro I, Carmona L, Balsa A, Sanmarti R, Belmonte MA, Tena X, and the EMECAR Study Group. Patterns of disease modifying antirheumatic drug use in a Spanish cohort of patients with rheumatoid arthritis. J Rheumatol 2003; 30: 697704.
  • 11
    Hamilton CD. Tuberculosis in the cytokine era: what rheumatologists need to know [editorial]. Arthritis Rheum 2003; 48: 208591.
  • 12
    Dinarello CA. Anti-cytokine therapeutics and infections. Vaccine 2003; 21 Suppl 2: S2434.
  • 13
    American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep 2000; 49: 151.
  • 14
    Sumartojo E. When tuberculosis treatment fails: a social behavioral account of patient adherence. Am Rev Respir Dis 1993; 147: 131120.
  • 15
    Bock NN, Metzger BS, Tapia JR, Blumberg HM. A tuberculin screening and isoniazid preventive therapy program in an inner-city population. Am J Respir Crit Care Med 1999; 159: 295300.
  • 16
    Gilroy SA, Rogers MA, Blair DC. Treatment of latent tuberculosis infection in patients aged ≥35 years. Clin Infect Dis 2000; 31: 8269.
  • 17
    Kopanoff DE, Snider DE, Caras GJ. Isoniazid related hepatitis. Am Rev Respir Dis 1978; 117: 9911001.
  • 18
    Vanhoof J, Landewe S, van Wijngaerden E, Geusens P. High incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with rheumatoid arthritis treated with methotrexate or sulfasalazine and anti-tumour necrosis factor inhibitors. Ann Rheum Dis 2003; 62: 12412.
  • 19
    Arts DG, de Keizer NF, Scheffer GJ. Defining and improving data quality in medical registries: a literature review, case study and generic framework. J Am Med Inform Assoc 2002; 9: 60011.
  • 20
    Van der Meulen JH, Jacob M, Copley L. Assessing the quality of the data in a transplant registry: the European Liver Transplant Registry. Transplantation 2003; 75: 21646.